Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
dc.contributor.author | Arellano, Jorge | en_US |
dc.contributor.author | Hernandez, Rohini K. | en_US |
dc.contributor.author | Wade, Sally W. | en_US |
dc.contributor.author | Chen, Kristina | en_US |
dc.contributor.author | Pirolli, Melissa | en_US |
dc.contributor.author | Quach, David | en_US |
dc.contributor.author | Quigley, Jane | en_US |
dc.contributor.author | Liede, Alexander | en_US |
dc.contributor.author | Shahinian, Vahakn B. | en_US |
dc.date.accessioned | 2015-06-01T18:51:58Z | |
dc.date.available | 2016-06-01T20:54:36Z | en |
dc.date.issued | 2015-05 | en_US |
dc.identifier.citation | Arellano, Jorge; Hernandez, Rohini K.; Wade, Sally W.; Chen, Kristina; Pirolli, Melissa; Quach, David; Quigley, Jane; Liede, Alexander; Shahinian, Vahakn B. (2015). "Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States." Cancer Medicine 4(5): 713-720. | en_US |
dc.identifier.issn | 2045-7634 | en_US |
dc.identifier.issn | 2045-7634 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111794 | |
dc.description.abstract | The renal status of patients with bone metastases secondary to solid tumors and their treatment with nephrotoxic agents is not well characterized. This retrospective study analyzed electronic medical records data from US‐based oncology clinics to identify adult (age ≥18) solid tumor patients with first bone metastasis diagnosis and ≥1 serum creatinine recorded between January 1, 2009 and December 31, 2013. Patients with multiple myeloma, multiple primary tumor types, acute renal failure, and/or end‐stage renal disease were excluded. Using the Chronic Kidney Disease Epidemiology Collaboration formula, we determined the prevalence of renal impairment (RI: single estimated glomerular filtration rate [eGFR] value <60 mL/min per 1.73 m2) and chronic kidney disease (CKD: ≥2 eGFR values <60, at least 90 days apart). We also examined the use of intravenous bisphosphonates (IV BP) and other nephrotoxic agents. Approximately half of the 11,809 patients were female. Breast (34%) and lung (28%) tumors were the most common. At bone metastasis diagnosis, mean age was 67 years and 24% of patients exhibited RI. The 5‐year prevalence was 43% for RI and 71% for CKD among RI patients. Nearly half (46%) of CKD patients received IV BP in the 12 months following their confirming eGFR and 13% of these patients received at least one other nephrotoxic agent during that period. This is the first US‐based study to examine the prevalence of RI among patients with bone metastases from solid tumors. RI is common at bone metastases diagnosis, and a substantial proportion of patients develop RI or CKD as their disease progresses. Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI.In patients with bone metastases secondary to solid tumors, the 5‐year prevalence was 43% for renal impairment (RI) and 71% for chronic kidney disease among evaluable RI patients. Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | solid tumor | en_US |
dc.subject.other | renal impairment | en_US |
dc.subject.other | intravenous bisphosphonates | en_US |
dc.subject.other | chronic kidney disease | en_US |
dc.subject.other | Bone metastasis | en_US |
dc.title | Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Hematology and Oncology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111794/1/cam4403.pdf | |
dc.identifier.doi | 10.1002/cam4.403 | en_US |
dc.identifier.source | Cancer Medicine | en_US |
dc.identifier.citedreference | Janus, N., et al. 2010. Cancer and renal insufficiency results of the BIRMA study. Br. J. Cancer 103: 1815 – 1821. | en_US |
dc.identifier.citedreference | Go, A. S., et al. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351: 1296 – 1305. | en_US |
dc.identifier.citedreference | Hemmelgarn, B. R., et al. 2010. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303: 423 – 429. | en_US |
dc.identifier.citedreference | Matsushita, K., et al. 2009. Change in estimated GFR associates with coronary heart disease and mortality. J. Am. Soc. Nephrol. 20: 2617 – 2624. | en_US |
dc.identifier.citedreference | Perkins, R. M., et al. 2011. GFR decline and mortality risk among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6: 1879 – 1886. | en_US |
dc.identifier.citedreference | Rifkin, D. E., et al. 2008. Rapid kidney function decline and mortality risk in older adults. Arch. Intern. Med. 168: 2212 – 2218. | en_US |
dc.identifier.citedreference | Shlipak, M. G., et al. 2009. Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am. J. Nephrol. 30: 171 – 178. | en_US |
dc.identifier.citedreference | Turin, T. C., et al. 2013. Change in the estimated glomerular filtration rate over time and risk of all‐cause mortality. Kidney Int. 83: 684 – 691. | en_US |
dc.identifier.citedreference | Turin, T. C., et al. 2012. Chronic kidney disease and life expectancy. Nephrol. Dial. Transplant. 27: 3182 – 3186. | en_US |
dc.identifier.citedreference | Gooley, T. A., et al. 2010. Reduced mortality after allogeneic hematopoietic‐cell transplantation. N. Engl. J. Med. 363: 2091 – 2101. | en_US |
dc.identifier.citedreference | Highlights of prescribing information for zoledronic acid (Zometa). Available at http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf (accessed 5 May 2014). | en_US |
dc.identifier.citedreference | Prescribing information for pamidronate disodium (Aredia). Available at http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf (accessed 5 May 2014). | en_US |
dc.identifier.citedreference | Levey, A. S., et al. 2009. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150: 604 – 612. | en_US |
dc.identifier.citedreference | Shahinian, V. B., et al. 2013. Estimating prevalence of CKD stages 3‐5 using health system data. Am. J. Kidney Dis. 61: 930 – 938. | en_US |
dc.identifier.citedreference | Launay‐Vacher, V., et al. 2007. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110: 1376 – 1384. | en_US |
dc.identifier.citedreference | Launay‐Vacher, V., et al. 2007. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann. Oncol. 18: 1314 – 1321. | en_US |
dc.identifier.citedreference | Launay‐Vacher, V., et al. 2009. Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin. Genitourin. Cancer 7: E83 – E89. | en_US |
dc.identifier.citedreference | Launay‐Vacher, V., et al. 2009. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187: 69 – 74. | en_US |
dc.identifier.citedreference | Launay‐Vacher, V., et al. 2010. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res. Treat. 124: 745 – 753. | en_US |
dc.identifier.citedreference | Aapro, M., and V. Launay‐Vacher. 2012. Importance of monitoring renal function in patients with cancer. Cancer Treat. Rev. 38: 235 – 240. | en_US |
dc.identifier.citedreference | Kleber, M., et al. 2007. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann. Oncol. 18: 950 – 958. | en_US |
dc.identifier.citedreference | Lichtman, S. M., et al. 2007. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J. Clin. Oncol. 25: 1832 – 1843. | en_US |
dc.identifier.citedreference | Oncologic drugs advisory committee meeting. Available at http://www.fda.gov/ohrms/dockets/ac/05/questions/2005-4095Q2_02_Zometa-Aredia-Questions.pdf (accessed 21 May 2014). | en_US |
dc.identifier.citedreference | Prescribing information for denosumab. Available at http://www.xgeva.com/xgeva-mechanism-of-action.html (accessed 21 May 2014). | en_US |
dc.identifier.citedreference | FDA approves Xgeva to help prevent cancer‐related bone injury. 2010. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm (accessed 21 May 2014). | en_US |
dc.identifier.citedreference | Henry, D. H., et al. 2011. Randomized, double‐blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29: 1125 – 1132. | en_US |
dc.identifier.citedreference | Stopeck, A. T., et al. 2010. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double‐blind study. J. Clin. Oncol. 28: 5132 – 5139. | en_US |
dc.identifier.citedreference | Fizazi, K., et al. 2011. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration‐resistant prostate cancer: a randomised, double‐blind study. Lancet 377: 813 – 822. | en_US |
dc.identifier.citedreference | Salahudeen, A. K., and J. V. Bonventre. 2013. Onconephrology: the latest frontier in the war against kidney disease. J. Am. Soc. Nephrol. 24: 26 – 30. | en_US |
dc.identifier.citedreference | C‐KIN/Cancer & the Kidney International Network. Available at http://www.c-kin.org/about-c-kin/ (accessed 17 November 2014). | en_US |
dc.identifier.citedreference | Perazella, M. A., and G. W. Moeckel. 2010. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin. Nephrol. 30: 570 – 581. | en_US |
dc.identifier.citedreference | Al‐Aly, Z., A. Zeringue, J. Fu, M. I. Rauchman, J. R. McDonald, T. M. El‐Achkar, et al. 2010. Rate of kidney function decline associates with mortality. J. Am. Soc. Nephrol. 21: 1961 – 1969. | en_US |
dc.identifier.citedreference | Cheng, T. Y., et al. 2008. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle‐aged working population in Taiwan. Am. J. Kidney Dis. 52: 1051 – 1060. | en_US |
dc.identifier.citedreference | Chronic Kidney Disease Prognosis Consortium, et al. 2010. Association of estimated glomerular filtration rate and albuminuria with all‐cause and cardiovascular mortality in general population cohorts: a collaborative meta‐analysis. Lancet 375: 2073 – 2081. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.